NANOSONICS LIMITED

Nanosonics Limited (ABN 11 095 076 896) and its controlled entities

Appendix 4E for the year ended 30 June 2026 (FY26)

Results for announcement to the market

	FY26 $000	FY25 $000	Change $000	Change %	Constant Currency Change %
Revenue	**203,893**	198,628	5,265	2.7%	6.5%
Earnings before interest and taxes	**15,998**	17,808	(1,810)	(10.2%)	20.5%
Profit before income tax	**20,112**	22,287	(2,175)	(9.8%)	15.0%
Profit from ordinary activities after tax attributable to members	**17,835**	20,676	(2,841)	(13.7%)	12.8%
Net profit for the period attributable to members	**17,835**	20,676	(2,841)	(13.7%)	12.8%

	FY26	FY25
Basic earnings per share (cents)	**5.90**	6.82
Diluted earnings per share (cents)	**5.77**	6.69

Overview

Nanosonics is a global leader in automated infection prevention solutions for medical device reprocessing. Its flagship trophon® technology has established a new standard for the high-level disinfection of ultrasound probes and helps protect more than 31 million patients each year. trophon delivers validated, repeatable and efficient reprocessing while reducing procedural variability. Building on this expertise, Nanosonics is advancing the CORIS® System, a groundbreaking automated technology for flexible endoscope cleaning, into commercialisation. The CORIS System has the potential to become the new standard of care in protecting over 60 million patients undergoing endoscope procedures annually. Nanosonics operates across North America, Europe, UK and Asia Pacific.

Explanatory note on the results

This report should also be read in conjunction with any public announcements made by Nanosonics in accordance with the continuous disclosure requirements arising under the Corporations Act 2001 (Cth) and ASX Listing Rules. The information provided in this report contains all the information required by ASX Listing Rule 4.3A. Foreign entities within the Group that prepare individual financial statements are in accordance with International Financial Reporting Standards (IFRS).

Dividends

No dividends were proposed, declared, or paid during the financial year (2025: Nil). During the year, the Company repurchased 5,546,728 (2025: Nil) shares for a total amount of $20 million under its on-market share buy-back program.

Net Tangible Asset Backing

Net tangible asset backing per share at 30 June 2026 was 66.01 cents (30 June 2025: 62.96 cents per share).

Entities where control has been gained or lost

There were no entities acquired or disposed of during the current period or the previous corresponding period. The entity had no associates or joint venture entities during the period or the prior corresponding period.

nanosonics
Infection Prevention. For Life.

Annual General Meeting

The annual general meeting will be held at Nanosonics Limited, Level 1 Building A, 7-11 Talavera Road, Macquarie Park NSW on 4 November 2026. A notice of meeting will follow.

This Appendix 4E should be read in conjunction with the Nanosonics Limited Financial Report for the year ended 30 June 2026. Included within the financial report is the Consolidated statement of profit or loss and other comprehensive income, Consolidated statement of financial position, Consolidated statement of cash flows, Consolidated statement of changes in equity together with explanatory notes.

Directors' resolution

The information set out above and in the Annual Report is provided to ASX in accordance with a resolution of the directors dated 25 August 2026.

Jason Burriss
Chief Financial Officer

25 August 2026